Copoly.ai

Copoly.ai is developing OncoSage, an AI-driven, blood-based diagnostic platform that enables non-invasive early cancer detection, starting with lung cancer. The platform delivers significantly higher sensitivity than conventional imaging or biopsy methods, addressing the challenge of late diagnoses. Its most advanced model, OncoSage Lung Cancer, has been validated in studies with over 1,400 patient samples, achieving 96.5% accuracy with precision and sensitivity, and specificity consistently above 90%, with particularly strong performance in detecting cancers at stage I.